# Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)

> **NCT06130332** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 40 (estimated)

## Conditions studied

- Oral Cancer
- PD-1

## Interventions

- **DRUG:** PD-1 with chemotherapy
- **PROCEDURE:** upright surgery

## Key facts

- **NCT ID:** NCT06130332
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2030-08-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06130332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06130332, "Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06130332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*